Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

$12 Billion US market drug of CLDA approved by FDA , will be worth even more Multi-Billions Worldwide.

|Includes:BIIB, Clinical Data, Inc. (CLDA), DNDN, LLY, MRK, PFE

$CLDA biotech ready to turn into EPS Momentum type stock with FDA approval.

Clinical Data (CLDA 23.80) initiated with a Mkt Outperform at Rodman & Renshaw; tgt $46. Firm believes that Viibryd's unique safety profile holds a substantial commercial potential and that Clinical Data may be an attractive acquisition target for large pharmaceutical companies. Firm estimates that Viibryd may reach a blockbuster status of $1B in annual sales within four years of launch, which we believe is reasonable based on the reported revenue for other recently launched antidepressants. Additionally, firm sees potential upside to their target price from a more successful launch, potential label expansion into other psychiatric indications for Viibryd, as well as the clinical and commercial success of Stedivaze, a Phase 3 drug that they did not include in the current valuation.

$CLDA barely trading +3/shr higher than Oct. high $20 Upside is huge there was no prior FDA approval run here, actually it was a sellof prior to the FDA news. Shorts were expecting FDA rejection and caused shares to selloff from $20 to low teens.

According to articles I have been reading: Viibryd will have $1+ Billion potential sales in USA alone. Once approved in other countries (other nations usually follow US FDA path) The potential sales will be in the multi billions per year worldwide. But for now the drug is entering a $12 billion market in the USA.